
Bionova Scientific Bionova Scientific®, commercial-scale biologics CDMO and a proud member of the Asahi Kasei Group, partners with innovators in the biologics industry to bring life-changing therapies to market with an unwavering dedication to quality and service. Founded in 2014 and acquired by Asahi Kasei in 2022, Bionova Scientific provides access to advanced technology platforms and scientific expertise spanning the full drug development lifecycle. As an integrated CDMO, Bionova provides end-to-end services spanning from discovery through cGMP commercial supply of complex therapeutic proteins and antibodies. Backed by a team of seasoned scientists, each with over 25 years of industry experience, our team helps clients overcome early development challenges and accelerate from discovery to first-in-human studies with efficient, scalable solutions. In 2025, Bionova expanded its capabilities with the launch of a dedicated plasmid DNA (pDNA) development and manufacturing facility in Houston, Texas—reinforcing our position as a trusted partner in advanced therapy production. With state-of-the-art facilities in both Houston and the San Francisco Bay Area, Bionova continues to support leading biotechnology innovators as a flexible, collaborative, and quality-focused partner. CDMO

Bionova Scientific

Bionova Scientific®, commercial-scale biologics CDMO and a proud member of the Asahi Kasei Group, partners with innovators in the biologics industry to bring life-changing therapies to market with an unwavering dedication to quality and service. Founded in 2014 and acquired by Asahi Kasei in 2022, Bionova Scientific provides access to advanced technology platforms and scientific expertise spanning the full drug development lifecycle. As an integrated CDMO, Bionova provides end-to-end services spanning from discovery through cGMP commercial supply of complex therapeutic proteins and antibodies. Backed by a team of seasoned scientists, each with over 25 years of industry experience, our team helps clients overcome early development challenges and accelerate from discovery to first-in-human studies with efficient, scalable solutions. In 2025, Bionova expanded its capabilities with the launch of a dedicated plasmid DNA (pDNA) development and manufacturing facility in Houston, Texas—reinforcing our position as a trusted partner in advanced therapy production. With state-of-the-art facilities in both Houston and the San Francisco Bay Area, Bionova continues to support leading biotechnology innovators as a flexible, collaborative, and quality-focused partner.

CDMO